Cargando…
Real-world efficacy of DA-EPOCH-R/HD-MTX regimen in CD5-positive diffuse large B cell lymphoma: a single-institute analysis
CD5-positive diffuse large B cell lymphoma (CD5+ DLBCL) is a high-risk lymphoma type. Recently, the PEARL5 (a Phase II trial of DA-EPOCH and Rituximab with HD-MTX therapy for newly diagnosed DLBCL with CD5 expression) study demonstrated the efficacy of the DA-EPOCH-R (cyclophosphamide, etoposide, do...
Autores principales: | Toyama, Kohtaro, Nakayama, Keita, Terasaki, Sachie, Matsumura, Ikuko, Kanaya, Shuhei, Iino, Hiromasa, Noguchi, Hiroyuki, Tahara, Kenichi, Yoshida, Takatomo, Saito, Akio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JSLRT
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158721/ https://www.ncbi.nlm.nih.gov/pubmed/36990773 http://dx.doi.org/10.3960/jslrt.22035 |
Ejemplares similares
-
Five‐year follow‐up of a phase II study of DA‐EPOCH‐R with high‐dose MTX in CD5‐positive DLBCL
por: Miyazaki, Kana, et al.
Publicado: (2023) -
Implementation of an Outpatient HD-MTX Initiative
por: Sokol, Kelsey, et al.
Publicado: (2022) -
ML-13 AN ATTEMPT OF RECHALLENGE OF HD-MTX AND MAINTENANCE THERAPY OF MTX FOR PATIENTS WITH PCNSL
por: Yamaguchi, Takashi, et al.
Publicado: (2019) -
To reduce the average length of stay of patients who are admitted for DA-EPOCH-R chemotherapy regimen
por: Lee, Yee Mei
Publicado: (2015) -
Relationship Between the Free and Total Methotrexate Plasma Concentration in Children and Application to Predict the Toxicity of HD-MTX
por: Dong, Wei-Chong, et al.
Publicado: (2021)